Skip to main content

Table 2 Characteristics of included studies

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Study Country Groups Patients (n) Median age (year) Stage Treatment line EGFRmutations Adenocarcinoma (%) Design Quality (score)
2010 Kim [19] Korea G vs. E 171/171 58/59 IIIb, IV 2, 3 86 RS 7
2010 Hotta [20] Japan G vs. E 330/209 68/68 II-IV or recurrent 2, 3 76 RS 9
2010 Hong [21] Keroa G vs. E 20/17 61/67 IIIb, IV 2, 3 75 RS 7
2011 Wu [22] Taiwan G vs. E 440/276 67/67 IIIb, IV 1 or later Partial 85 RS 9
2011 Shin [12] Keroa G vs. E 100/82 65/65 III, IV 2 Partial 0 RS 7
2011 Togashi [23] Japan G vs. E 85/69 65/68 IIIb, IV 1 or later Partial 82 RS 8
2011 Fan [14] Taiwan G vs. E 715/407 IIIb, IV 1 or later Partial 77 RS 8
2011 Jung [24] Korea G vs. E 72/51 55/55 IIIb, IV 1 or later Partial 59 RS 6
2012 Wu [25] Taiwan G vs. E 124/100 IIIb, IV 1 or later Partial 100 RS 8
2012 Kim [26] Keroa G vs. E 48/48 59/60 IIIb, IV 2 Partial 91 RCT 4
2012 Suzumura [27] Japan G vs. E 232/86 67/66 IIIb, IV Partial 95 RS 8
2013 Yoshida [28] Japan G vs. E 107/35 64/67 III, IV or recurrent 1 or later Partial 84 RS 8
2013 Shao [29] Taiwan G vs. E 655/329 61/63 IIIb, IV or recurrent 3 80 RS 9
2013 Lee [30] Korea G vs. E 11/14 49/58 IV 1 or later Partial 92 RS 8
2013 Yu [31] China G vs. E 16/22 54/52 3 Partial 100 RS 8
2014 Lim [32] Korea G vs. E 121/121 58/58 IIIb, IV 1 or later All 98 RS 9
2014 Sato [13] Japan G vs. E 213/69 66/66 IIIb, IV or recurrent Partial 86 RS 8
2014 Lin [33] China G vs. E 57/24 IIIb, IV 1 All 59 RS 7
2014 Ren [34] China G vs. E 60/142 59/59 IV 1 or later Partial 66 RS 8
2014 Li [35] China G vs. E 53/97 59/59 IIIb, IV 2 Partial 67 RS 8
2014 Takeda [36] Japan G vs. E 57/11 69/69 III, IV or recurrent 1 or later All 99 RS 6
2015 Otsuka [37] Japan G vs. E 35/9 70/62 IIIb, IV 1 or later All 91 RS 9
2015 Song [38] China G vs. E 37/65 75/75 IIIb, IV 2 or later Partial 83 RS 7
2015 Koo [39] Korea G vs. E 166/56 IV 1, 2, 3 All 87 RS 7
2016 Ruan [40] China G vs. E 63/134 59/60 III, IV All RS 8
2016 Hirano [41] Japan G vs. E 10/16 71/71 IB-IV or recurrent All 81 RS 8
2016 Urata [10] Japan G vs. E 279/280 68/67 IIIb, IV or recurrent 2, 3 Partial 100 RCT 5
2016 Suh [42] Korea G vs. E 146/5 65/65 IIIb, IV 1 All 97 RS 7
2016 Kashima [43] Japan G vs. E 52/11 68/68 IV All RS 8
2017 Yang [11] China G vs. E 128/128 IIIb, IV 1, 2 All 96 RCT 5
2017 Kuan [15] Taiwan G vs. E 304/63 65/67 IIIb, IV 1 All RS 8
  1. Abbreviations: G gefitinib, E erlotinib, EGFR epidermal growth factor receptor, RS retrospective study, RCT randomized controlled trial, −: not available